Meta-Analysis of Sotagliflozin, a Dual Sodium-Glucose-Cotransporter 1/2 Inhibitor, for Heart Failure in Type 2 Diabetes
Pooled result · HFResult — go to the resultRelative risk 0.66 95% CI 0.64–0.69Authors' conclusion
Sotagliflozin reduced HF and cardiovascular events in type 2 diabetes participants.
Study context
- Population
- Participants with T2DM
- Participants
- 15,320 participants · 9 studies
- Comparison
- Sotagliflozin vs control
- Sotagliflozinn = 8,040
- Controln = 7,280reference
- Outcome
- HF events
- Follow-up
- >52 weeks
Methodological detailsMedian follow-up 13.4 months (Q1 = 13, Q3 = 21), High risk of bias (RoB 2.0) noted as a limitation
- Median follow-up 13.4 months (Q1 = 13, Q3 = 21)
- High risk of bias (RoB 2.0) noted as a limitation
Pooled result
HF
Relative risk
0.66
95% CI 0.64–0.69
Sotagliflozin vs Control
RR 0.66 (95% CI 0.64–0.69)
As reported in the abstract
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| Stroke · follow-up >52 weeksn = 6 studies | 0.75 (0.58–0.97) | |
| MACE · follow-up >52 weeksn = 8 studies; NNT 26 | 0.73 (0.66–0.81) | |
| 0.512Relative risk (log scale) |
| Outcome | MD (mmHg) (95% CI) | |
|---|---|---|
| SBPn = 7 | −2.38 (−2.79 to −1.97) | |
| −4−202Difference, mmHg (linear scale) |
Heart failure (HF) by sotagliflozin dose
- No dose-dependent effect for HF
- P = 0.22
- 200 mg: RR
- 0.38 (0.16, 0.89)
- 400 mg: RR
- 0.57 (0.39, 0.85)
Original publication
Meta-Analysis of Sotagliflozin, a Dual Sodium-Glucose-Cotransporter 1/2 Inhibitor, for Heart Failure in Type 2 Diabetes. ESC Heart Fail. Published 10 September 2024. doi:10.
Summarised from the published abstract; every number is checked against it